Zimycan distribution
This article was originally published in The Tan Sheet
Executive Summary
Ft. Worth, Texas-based Healthpoint gets exclusive rights to market Barrier Therapeutics' antifungal ointment Zimycan to healthcare institutions in the U.S. and Canada under an agreement announced Sept. 13. Barrier cites Healthpoint's tissue management division as a good match for the product. The firm announced positive Phase III trial results for the candida-associated diaper rash cream in August after licensing the drug from Johnson & Johnson, where it had failed to gain approval as an OTC (1"The Tan Sheet" Aug. 16, 2004, p. 9). Barrier's NDA for Zimycan is currently pending at FDA...
You may also be interested in...
OTC Misfire Salvaged As Rx Prospect: Barrier Touts Antifungal Zimycan Trial
Barrier Therapeutics plans to parlay Johnson & Johnson's failed over-the-counter diaper cream Zimycan into the first prescription treatment for diaper rash complicated by Candida yeast infection
RB Doubles R&D Spend In Search Of 'Game Changing’ OTC Innovation
With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.
JHL Becomes Eden And Announces Denosumab Progress
Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: